# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outl...
Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price targ...
U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday.
- SEC Filing
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed four...
Goldman Sachs analyst Matthew Sykes maintains Cytek Biosciences (NASDAQ:CTKB) with a Buy and raises the price target from $9...
Cytek Biosciences (NASDAQ:CTKB) reported quarterly sales of $58.60 million which beat the analyst consensus estimate of $56.58 ...